Effects of EVT 302 With or Without NRT on Craving and Withdrawal in Healthy Male Smokers Deprived of Cigarettes

This study has been completed.
Sponsor:
Information provided by:
Evotec Neurosciences GmbH
ClinicalTrials.gov Identifier:
NCT00622752
First received: February 13, 2008
Last updated: June 16, 2008
Last verified: June 2008

February 13, 2008
June 16, 2008
February 2008
May 2008   (final data collection date for primary outcome measure)
Reduction in Craving and withdrawal [ Time Frame: Within 12 hours of the last cigarette ] [ Designated as safety issue: No ]
Same as current
Complete list of historical versions of study NCT00622752 on ClinicalTrials.gov Archive Site
  • CogState Cognitive test Battery [ Time Frame: 12 hours post last cigarette ] [ Designated as safety issue: No ]
  • Breath carbon monoxide levels [ Time Frame: 12 hours post last cigarette ] [ Designated as safety issue: No ]
  • Salivary cotinine levels [ Time Frame: 12 hours post last cigarette ] [ Designated as safety issue: No ]
  • Clinical safety lab tests [ Time Frame: Up to 7 days post dose ] [ Designated as safety issue: Yes ]
  • Assessment of adverse events [ Time Frame: Up to 7 days post dose ] [ Designated as safety issue: Yes ]
Same as current
Not Provided
Not Provided
 
Effects of EVT 302 With or Without NRT on Craving and Withdrawal in Healthy Male Smokers Deprived of Cigarettes
A Double-Blind, Randomized, Placebo- and NRT -Controlled Phase II Study to Assess the Effects of EVT 302 Alone and in Combination With NRT on Craving and Withdrawal in Healthy Male Smokers Deprived of Cigarettes

This randomised, placebo-controlled study is designed to explore the effects of EVT 302 both with and without concomitant nicotine replacement therapy (NRT) on craving and withdrawal in smokers after short term deprivation of cigarettes.

Not Provided
Interventional
Phase 2
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Crossover Assignment
Masking: Double Blind (Subject, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Smoking Cessation
  • Drug: EVT 302, 10 mg
    2 X EVT 302, 5 mg tablets
  • Drug: placebo
    2 X placebo tablets to match EVT 302 5 mg
  • Drug: Nicotine replacement therapy (NRT)
    NRT patch containing 21 mg of nicotine
  • Device: NRT placebo
    Medically inert plaster cut to match the NRT plaster
  • Experimental: 1
    EVT 302, 10 mg
    Intervention: Drug: EVT 302, 10 mg
  • Experimental: 2
    EVT 302, 10 mg + NRT patch, 21 mg
    Interventions:
    • Drug: EVT 302, 10 mg
    • Drug: Nicotine replacement therapy (NRT)
  • Experimental: 3
    NRT patch, 21 mg
    Intervention: Drug: Nicotine replacement therapy (NRT)
  • Placebo Comparator: 4
    Placebo to match EVT 302 and placebo patch to match NRT patch
    Interventions:
    • Drug: placebo
    • Device: NRT placebo
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
90
May 2008
May 2008   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Male subjects between 18 and 55 years of age, inclusive
  • BMI between 18 and 30, minimum weight of 50 kg
  • Negative urine drug & alcohol screen
  • Able to comply with tyramine-restricted diet
  • Smoking of ≥17 and ≤34 cigarettes per day for the past year and have not tried to quit smoking in the 3 months prior to screening
  • Subjects are willing and able to quit for about 12 hours in each of three subsequent study periods
  • Previous experience of craving following smoking cessation
  • Breath CO between 15 ppm and 20 ppm and cotinine in saliva and plasma at least 250 ng/mL at screening
  • Liver function test results not above 1.5 times the upper normal limit (UNL) at screening visit and at re-assessment during the study.

Exclusion Criteria:

  • Participation in another clinical study within 60 days of screening
  • Evidence of active significant psychiatric or neurological disease or dependency other than cigarettes
  • Are known to have or are a carrier of the hepatitis B surface antigen (HBsAg), hepatitis C virus (HCV) antibody, has a positive result to the human immunodeficiency virus-1 and/or 2 (HIV-1 and/or HIV-2) antibodies
  • Known hypersensitivity to MAO inhibitors or any substance that is contained in the study formulations
  • Known allergy to plasters or NRT patches
  • Previous participation in another study with EVT 302
  • Currently receiving treatment for smoking cessation
  • Current use of tobacco products other than cigarettes
  • Require treatment with any medication
  • Subject with a clinically relevant abnormal 12-lead ECG recording or QTcB/F >430 ms
  • Use of a prescription medicine within 14 days or 5 half-lives, whichever is the longer, of the start of dosing, or use of an over-the-counter medication during the 7 days before the study, including herbal remedies, but excluding paracetamol and vitamin supplements (provided intake does not exceed the daily recommended allowance)
  • Subjects must not be planning to father a child or donate sperm, during the study and 3 months after the end of the study. Acceptable methods of contraception comprise barrier contraception and a medically accepted contraceptive method for the female partner (intra-uterine device with spermicide, hormonal contraceptive since at least 2 month)
  • Daily consumption of more than 5 cups of tea or coffee, or more than 1.0 litre of xanthine-containing drinks
  • Recent myocardial infarction, unstable or worsening angina pectoris, prince metal angina, severe arrhythmias, recent stroke.
  • Creatinine clearance (CLR) calculated according to the formula by Modification of Diet in Renal Disease (MDRD) of <80 mL/min
Male
18 Years to 55 Years
No
Contact information is only displayed when the study is recruiting subjects
Germany
 
NCT00622752
EVT 302/3011, EUDRACT No.: 2007-006236-63
No
Doris Greiling, Clinical Development Programme Manager, Evotec Neurosciences GmbH
Evotec Neurosciences GmbH
Not Provided
Principal Investigator: Alla Radicke, MD Parexel International GmbH, Clinical Pharmacology Research Unit
Evotec Neurosciences GmbH
June 2008

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP